BofA downgraded Ambev (ABEV) to Neutral from Buy with a price target of $2.10, down from $2.80. The firm noted that Ambev had a successful turnaround over the last five years, driven by “a very ...
Barclays analyst Benjamin Theurer lowered the firm’s price target on Ambev (ABEV) to $2 from $2.50 and keeps an Equal Weight rating on the shares. Entering 2025, the firm is more optimistic ...
Ambev S.A. offers strong revenue growth, high operating margins, and a solid balance sheet with minimal debt, making it a compelling investment despite Brazil's economic challenges. ABEV is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback